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Objectives. This study compared the efficacy and safety of 
sotalol and quinidine for conversion and prevention of recurrent 
atrial fibrillation. 
Background. Atrial fibrillation is the most common arrhyth. 
mia. Pharmacologic therapy has been advocated forboth imme- 
diate restoration of sinus rhythm and prevention of recurrent 
atrial fibrillation. Quinidine is the therapeutic mainstay for both 
purposes, but its safety has recently been questioned. Although 
sotalol has been used successfully to maintain sinus rhythm after 
direct current cardioversion, its efficacy in pharmacologically 
reverting atrial fibrillation has not been examined. 
Methods. Fifty consecutive patients with persistent atrial fibril- 
lation were randomized to receive quinidine or sotalol for up to 7 
days to restore sinus rhythm. Patients were followed up for 6 
months. 
Results. Quinidine was more effective than sotalol in terminat- 
ing atrial fibrillation (60% vs. 20%, p = 0.009). When nonre- 
sponders to drug therapy underwent subsequent direct current 
cardioversion, total conversion rates in the quinidine and sotalol 
groups were comparable (88% vs. 68%, p = 0.17), as was the 
efficacy of the two drugs in preventing recurrent atrial fibrillation. 
Side effects necessitating dru  discontinuation were more often 
observed with quinidine. No patient receiving sotalol but four 
patients receiving quinidine had drug-associated arrhythmia (tor- 
sade de pointes in three patients, sustained v ntricular tachycar- 
dia in one patient). Precordial QT dispersion determined on the 
surface electrocardiogram (ECG) increased with quinidine 
(mean -+ SD 34 _ 9 vs. 44 -+ 16 ms, p = 0.02), indicating enhanced 
inhomogeneity in ventricular repolarization. There was no change 
in QT dispersion in patients receiving sotalol (36 -+ 18 vs. 40 -+ 
17 ms, p = 0.44). 
Conclusions. Quinidine is more effective than sotaloi n termi- 
nating atrial fibrillation but is associated with more side effects. 
The proarrhythmic risk may be related to quinidine's propensity 
to increase disparity in ventricular repolarization. This risk 
warrants careful ECG monitoring during the 1st 4 to 7 days of 
therapy. Because most proarrhythmic effects o curred shortly 
after estoration ofsinus rhythm, observation should continue _>2 
to 3 days after sinus rhythm is reestablished. 
(J Am CoU Cardiol 1995;26:852- 8) 
Atrial fibrillation is the most commonly encountered cardiac 
arrhythmia, affecting 2% to 4% of a general middle-aged 
population (1,2). Therapy with quinidine, either alone or in 
combination with verapamil, has long been considered the 
standard therapy for this arrhythmia to obtain both immediate 
restoration and maintenance of sinus rhythm (3-10). However, 
concerns have been raised with respect to the safety of 
quinidine therapy (11,12). These concerns tem mainly from a 
meta-analysis of quinidine trials performed by Coplen et al. 
(11), who demonstrated more deaths in patients receiving 
quinidine for maintenance of sinus rhythm than in patients 
receiving placebo. Similar concerns have become vident in a 
retrospective analysis of the Stroke Prevention n Atrial Fibril- 
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lation (SPAF) trial, which also indicated an increased risk for 
patients with atrial fibrillation treated with antiarrhythmic 
drugs, especially when congestive heart failure was present 
(12). The results of these and other studies have raised interest 
in the evaluation of newer antiarrhythmic drugs for use in 
symptomatic atrial fibrillation (9). Sotalol, a beta-receptor 
antagonist with additional class III antiarrhythmic properties 
(13), has been successfully used to prevent recurrent atrial 
fibrillation in patients after electrical cardioversion (14,15). 
However, no controlled trials have yet been performed to 
evaluate the efficacy of sotalol in restoring sinus rhythm in 
patients with atrial fibrillation. 
Thus, the present prospective randomized trial compared 
the efficacy of quinidine and sotalol for both restoration a d 
maintenance of sinus rhythm in patients with symptomatic 
chronic atrial fibrillation of recent onset. The safety profile of
both substances was also evaluated uring the acute drug 
titration phase and during a 6-month follow-up period, with 
particular attention given to the development of drug-related 
proarrhythmic reactions. For this purpose, dispersion of QT 
interval duration (16,17) was determined in the surface lec- 
trocardiogram (ECG) during a drug-free baseline period and 
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during therapy. This method was recently demonstrated (18- 
20) to be potentially useful for identifying increased risk of 
antiarrhythmic drug-induced proarrhythmia. 
Methods 
Study patients. Patients with chronic atrial fibrillation re- 
ferred to the arrhythmia services of the University Hospital 
Freiburg were eligible for inclusion in this study if they met the 
following entry criteria: 1) age 18 to 80 years; 2) ECG- 
documented persistent atrial fibrillation with a continuous 
duration between 48 h and 6 months; 3) symptoms such as 
palpitation, dyspnea, chest pain or light-headedness in associ- 
ation with atrial fibrillation; 4) provision of i formed consent. 
Exclusion criteria for participation i the trial were 1) acute 
myocardial infarction <4 weeks before entry in the study; 2) 
unstable angina pectoris; 3) congestive heart failure of New 
York Heart Association class IV; 4) uncorrected electrolyte 
disturbances (e.g., serum potassium <4.0 mEq/liter or magne- 
sium <1.5 mEq/liter); 5) chronic obstructive pulmonary dis- 
ease; 6) compromised renal function (i.e., serum creatinine 
>1.8 mg/dl); 7) hepatic insufficiency; 8) hyperthyroidism; 
9) previous treatment with quinidine or sotalol; 10) concomi- 
tant therapy with other class I to IV antiarrhythmic agents. 
Baseline measurements. Before patients were entered into 
the study, baseline demographic data including all relevant 
cardiac diagnoses, history and physical examination, laboratory 
results (electrolytes, renal and liver function tests, digoxin 
serum concentration, coagulation variables) were obtained. 
One- and two-dimensional echocardiography was performed 
with determination of left atrial size and left ventricular 
ejection fraction. All echocardiographic recordings were re- 
viewed by two experienced observers. In addition to recording 
of several ECGs at rest during the drug-free baseline period, 
24-h ambulatory ECG monitoring was performed. All patients 
received stable maintenance dosages of digoxin and anticoag- 
ulant herapy with warfarin sodium (Coumadin) or intravenous 
heparin (partial thromboplastin time adjusted to two imes the 
upper limit of normal) for ->8 days before attempted cardio- 
version. Treatment of underlying heart disease was optimized 
and kept constant in all patients throughout the study. 
Drug treatment schedule. On completion of baseline eval- 
uation, patients were randomly assigned to therapy with quin- 
idine or sotalol. A test dose of quinidine (quinidine sulfate, 
200 mg) was followed by administration of a slow release 
preparation of 500 mg twice daily for the 1st 3 days. After 3 
days of ineffective therapy, quinidine at a dose of 250 mg was 
administered together with verapamil (80 mg four times daily) 
for the next 4 days (5,7,8). Sotalol therapy was initiated at 
80 mg twice daily at day I and at 160 mg twice daily for the next 
6 days. In patients with drug-related side effects, sotalol c uld 
be titrated ownward to 240 or 160 mg/day. All patients were 
hospitalized throughout this dose titration phase. Rest ECGs 
were recorded 2 h after the first drug dose and daily thereafter. 
Blood samples for determination f serum electrolytes were 
taken every other day. Repeat 24-h ambulatory ECG monitor- 
ing was performed immediately on restoration ofsinus rhythm, 
or on day 7 in patients with persistent atrial fibrillation. 
Electrical cardioversion was attempted on day 8 in patients 
with persistent atrial fibrillation despite therapy with one of the 
study medications while randomized antiarrhythmic drug ther- 
apy was continued. Direct current conversion was started at an 
nergy level of 100 W and, if necessary, repeated twice at 
increasing energy levels (maximal energy delivered 320 W). 
After the procedure, the patient was closely observed an  the 
ECG was continuously monitored for 8 h. 
Long.term follow-up. All patients were followed up in the 
outpatient clinic at 2 and 6 months. In patients with successful 
pharmacologic or electrical restoration of sinus rhythm, anti- 
coagulation with Coumadin was continued for 4 weeks. Pa- 
tients with persistent atrial fibrillation received ontinuous 
anticoagulation. The study medication was continued in drug 
responders to prevent recurrent atrial fibrillation and in non- 
responders tocontrol heart rate. During all visits, a 12-lead rest 
ECG was recorded, and routine laboratory tests were per- 
formed. Side effects of the study medication were noted and 
the dosage was adjusted where appropriate. In addition, 
echocardiography and 24-h ambulatory ECG monitoring were 
repeated at 6 months. 
QT dispersion analysis. All 12 standard ECG leads were 
recorded by means of a six-channel ECG recorder (Siemens 
Mingograph 704, Erlangen, Germany) at a paper speed of 
50 mm/s. For analysis of dispersion of QT interval duration, 
the RR and QT intervals were measured in the six precordial 
leads (20) by means of a digitizing tablet (Digitizer KD 3200, 
Graphtec Corporation, Japan) interfaced to a personal com- 
puter. The cursor of the digitizing tablet was equipped with a 
magnifying lass to enhance the accuracy of detection of the 
beginning and end of the QT intervals. Each measurement is 
given as the mean value of two to three consecutive RR and 
QT intervals. The QT interval was measured from the first 
deflection of the QRS complex to the point of T wave offset, 
which was defined by the return of the terminal T wave to the 
isoelectric baseline. In the presence of a U wave interrupting 
the T wave, the terminal portion f the visible T wave was 
extrapolated to the baseline to define the point of T wave 
offset. If the end of the T wave could not be reliably deter- 
mined, the lead was not included in the analysis. QT dispersion 
was defined in each ECG as the difference between the 
maximal and the minimal QT interval in any of the leads 
measured. In our laboratory (21) there is good intraobserver 
and interobserver variability of repeated QT dispersion mea- 
surements, with correlation coefficients ranging from 0.84 to 
(}.93. 
Statistical analysis. The data were fed into a data base 
(MS Excel Version 4.0) for further statistical analysis. All data 
are given as mean value _ SD. Data analysis was performed on 
the intention-to-treat principle. Comparisons were performed 
by means of the chi-square test and two-way repeated mea- 
sures analysis of variance where appropriate. Statistical signif- 
icance was assumed with an alpha level of 0.05. 
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Table 1. Clinical Characteristics of the Study Patients 
All Patients Ouinidine Group Sotalol Group 
(n -- 5{1) (n 25) (n 25) 
Age (yr) 62 ~ 11 (~5 + 13 f~0 + 10 
Gender 
Men 18 (36%) I0 (400() 8 (3292 I 
Women 32 (64~c) 15 160% ) 17 (b8q/) 
Cardiac disease 
CAD 15 (30%) f> (24%) (9 (3b¢;) 
Valvular 14 (28~) S (32¢'~) 6 (24q) 
Hypertensive 10 (2()< + ) ~ i24% ) 4 ( 16% )
Cardiomyopathy 4 (8(~) 2 (8(~) 2 (8%) 
Lone Afib 7 ( 14(;~ ) 3 112(:i ) 4 ( I(~% )
Duration of Atib 
Mean (days) 44 +_ 56 3c) + 48 4 t) + b3 
Median (days) 20 21 20 
Mean HR t,10 + 18 (57 150) NN + 21 t q + 15 
(beats/rain) 
Maximal HR 153 + 33 (69-210) 149 - 33 157 + 34 
(beats/min) 
Minimal HR 53 + 17 (30-1181 54 + 19 q:~ -' 15 
(beats/rain) 
Data are expressed as mean value , SD(range! or number ((,f) t)f patients. 
Afib = alrial fibrillation: CAD :, coronary artery disease: HR = heart rate. 
Results 
Clinical characteristics of study patients. Fifty consecutive 
patients meeting inclusion and exclusion criteria were enrolled 
into the trial. There were 32 men and 18 women with a mean 
age of 62 _+ 11 years (Table 1). Most patients (86~-) had 
organic heart disease: lone atrial fibrillation was present in only 
seven. The average duration of atrial fibrillation was 44 _+ 5(1 
days. As expected, there were no significant differences in 
clinical characteristics in quinidinc- and sotalol-treated pa- 
tients (Table 1). Left atrial diameter averaged 50 + 7 ram, left 
ventricular end-diastolic diameter 52 _+ 7 mm and left vcntric- 
ular ejection fraction 51 _+ 10'77;. Again. there were no differ- 
ences in these variables between the two patient groups. 
Response to randomized therapy. In the quinidine group, 
15 (60%) of the 25 patients had conversion to sinus rhythm 
during the 1st 7 days of therapy. Quinidine was administered 
an average of 3.9 _+ 1.8 days before sinus rhythm was restored; 
in three patients, atrial flutter preceded the restoration of sinus 
rhythm. Of the 25 patients treated with sotalol, only 5 (20%) 
had sinus rhythm successfully restored. In these five patients, 
sotalol was administered on average 3.6 _+ 1.8 days (Fig. 1); 
none of the five patients had atrial flutter before conversion to 
sinus rhythm. The difference between the two treatment 
groups with respect to termination of atrial fibrillation was 
highly significant (p = 0.009). In 26 of 30 nonresponders to 
drug therapy, direct current cardioversion was attempted; the 
remaining four nonresponders did not agree to undergo elec- 
trical cardioversion. Electrical cardioversion restored sinus 
rhythm in 19 patients, 7 from the quinidine and 12 from the 
sotalol group. Thus, at he end of the combined pharmacologic 
and electrical cardioversion protocol, 22 (88%) of the 25 
patients treated with quinidine and 17 (68%) of the 25 patients 
treated with sotalol had sinus rhythm (p = 0.17). 
Several clinical variables were xamined in an attempt o 
identify patient characteristics that would allow prediction of 
the response to quinidine or sotalol. The presence of organic 
heart disease versus lone atrial fibrillation, left atrial or left 
ventricular diameter, left vcntricular ejection fraction and 
heart rate at baseline or during drug therapy did not differ in 
patients responding to one of the two therapeutic regimens. 
The only variable that differed between groups was the average 
duration of atrial fibrillation before initiation of therapy: 
Patients responding to quinidine had atrial fibrillation for an 
average of 32 +_ 26 days, whereas patients with successful 
sotalol therapy had had a diagnosis of atrial fibrillation for only 
7 _+ 7 days (p = 0.005). 
Drug-induced changes in ECG variables. Heart rate re- 
sponse to drug therapy was comparable in the two treatment 
groups. Mean heart rate as assessed from ambulatory ECG 
recording was 88 +_ 21 and 90 _+ 15 beats/min in the quinidine 
Responder[%] 
lOO 
9o 
80 
70 
6o 
50 
4o 
30 
20 
lO 
o 
1 
Mean durat ion of therapy (days): 
Qu in id ine  3.9 + 18  ' - 
Sotalol 36  + 18  - - : :  
I 
'1 . . . . .  
I 
i 
I > 
I 
I 
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3 4 5 6 7 
Duration of therapy (days) 
2 
Figure l. Duration of pharmacologic therapy 
until restoration of sinus rhythm. The total num- 
ber of patients responding to pharmacologic 
therapy is set as 100% (20 patients). On average, 
4 days of therapy was necessary to terminate 
atrial fibrillation in these responders. 
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Figure 2. Drug-induced changes in heart rate as assessed by 24-h 
ambulatory, electrocardiographic monitoring. Both drugs reduced 
heart rate to a similar extent from the baseline level, bpm = beats per 
minute. Solid bars : quinidine; open bars : sotalo[. 
and sotalol groups, respectively. The respective values during 
drug administration were 74 _+ 14 and 69 + 16 beats/rain (p - 
0.001 vs. baseline, Fig. 2). Similar changes were observed for 
maximal and minimal heart rates. There were no changes in 
QRS duration between the drug-free control condition and 
therapy with either quinidine or sotalol. The maximal QT 
interval increased in the quinidine group from 363 _+ 38 ms to 
411 _+ 39 ms (p < 0.01). The changes in QT duration were 
similar in the sotalol group (367 + 40 vs. 425 + 58 ms, p < 
0.01). However, QT dispersion as assessed in the precordial 
ECG leads increased significantly only in the quinidine group 
(from 34 + 9 to 44 + 16 ms, p = 0.02). In all three patients with 
quinidine-associated orsade de pointes (see later), QT disper- 
sion increased by >50% of the control value. Sotalol-treated 
patients howed no significant changes in average QT disper- 
sion (36 _+ 18 vs. 40 _+ 17 ms, p = 0.44; Fig. 3). 
Long-term e~eacy of therapy. Twenty-one patients treated 
with quinidine versus 17 treated with sotalol were discharged 
from the hospital with sinus rhythm. At the 2-month follow-up 
visit, 5 (24%) of 21 quinidine-treated patients had a recurrence 
of atrial fibrillation. Two of the five patients underwent repeat 
direct current cardioversion. Thus, at 6 months 18 (86%) of the 
21 patients in the quinidine group discharged with sinus 
rhythm were classified as long-term responders on an inten- 
tion-to-treat basis. In the sotalol group, 4 (24%) of the 17 
patients discharged with sinus rhythm had a recurrence of 
atrial fibrillation at 2 months. One other patient who had been 
discharged while receiving sotalol for persistent atrial fibrilla- 
tion showed late conversion to sinus rhythm. Thus, 14 patients 
in the sotalol group were classified as rcsponders; of these, 1 
patient had a recurrence of atrial fibrillation at 6 months, 
resulting in a long-term success rate of 77% in the sotalol 
group. This overall long-term elficacy rate was comparable to 
the 86% rate in the quinidine group. 
Safety of randomized therapy. Side effects were commonly 
observed in both treatment groups. They were reported in 11 
QT dispersion [rnsec] 
7O 
p = 002 
- - 1  p=044 
60 i r - - I  
F 
so f 
40 
:30 
20 
10 
0 
Quinidine Sotalol 
Figure 3. Drug-associated changes in QT dispersion (defined as the 
difference between the maximal and the minimal QT interval in any of 
the electrocardiographic leads measured) as assessed from precordial 
leads. At baseline, 0T dispersion was comparable inthe two treatment 
groups. Solid bars = baseline; open bars = drug therapy. 
(44%) of the 25 sotalol-treated patients and 14 (56%) of the 25 
patients receiving quinidinc (p = 0.57). The most commonly 
observed unwanted reaction in patients treated with sotalol 
was sinus bradycardia, which had been prospectively defined 
for the purpose of this study as a sinus rate -<45 beats/rain with 
or without symptoms. In two patients, symptoms of congestive 
heart failure exacerbated during therapy with sotalol. Second 
degree atrioventricular block (Mobitz type I) occurred in one 
patient after restoration of sinus rhythm. In all but one patient, 
these sotalol-associated si e effects disappeared on downward 
dose titration according to the study protocol. 
In the quinidine group, the most commonly encountered 
side effects were gastrointestinal in origin (seven patients). 
Sinus bradycardia -<45 beats/rain was observed in two patients, 
aggravation of congestive heart failure in one patient. Four 
patients had proarrhythmic effects: three patients with torsade 
de pointes and one patient with sustained monomorphic 
ventricular tachycardia. In two patients, torsade de pointes 
tachycardia degenerated into ventricular fibrillation. In three 
of the four patients, the arrhythmia occurred shortly after 
restoration of sinus rhythm (Table 2). Quinidine plasma 
concentrations at the time of the event were available in three 
of the four patients and were within the normal range of 3 to 
8 gl/ml (22). As a result of these adverse reactions, quinidine 
administration was stopped in 10 of 14 patients (p = 0.004 vs. 
the sotalol group). 
Discuss ion  
Summary of study findings. This prospective study com- 
pared the efficacy and safety of quinidine and sotalol in 
converting atrial fibrillation to normal sinus rhythm and in 
preventing recurrent episodes of atrial fibrillation during a 
6-month follow-up period. It differs in several aspects from 
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Table 2. Characteristics of the Four Patients With Quinidine-Associated Proarrhythmic Responses 
Time of 
Pt Heart Occurrence, QT ...... LA LVEF Drug Plasma Level 
No. Disease SR/Afib (ms) (mm) (%) (~g/ml) 
1 Dilative cardiomyopathy Day 4, SR 420 50 27 2.7 
2 Lone Afib Day 7, SR 550 42 60 4.1 
3 Valvular Day 5, SR 450 47 45 3.7 
4 Valvular Day L Afib 520 71 55 . . .  
Afib = atrial fibrillation: LA = left atrium; LVEF - left ventricular ejection fraction; Pt = patient; QT .... - maximal 
QT interval; SR = sinus rhythm; . . .  = not available. 
previous investigations. 1) Sotalol had not been evaluated 
systematically with respect to its potential for converting atrial 
fibrillation to sinus rhythm. In this regard, sotalol--at least in 
the dose range used here--was significantly less effective 
compared to quinidine, which is still the antiarrhythmic drug 
most commonly used for this purpose in many institutions (9). 
2) When pharmacologic therapy was combined with electrical 
cardioversion, the effectiveness of the two therapeutic regi- 
mens tested was comparable. Similarly, the two drugs were 
comparably effective in preventing recurrent atrial fibrillation 
during follow-up. 3) A time interval of ->4 to 7 days appears 
necessary to reliably assess uccess or failure of sole pharma- 
cologic conversion therapy, even in patie ts with atrial fibril- 
lation of short duration. 4) Our findings ubstantiate previous 
concerns about the safety of pharmacologic conversion with 
quinidine. Even considering our small patient sample size, this 
drug was more often associated with proarrhythmic hazards 
than sotalol. 5) This study is one of the first to provide evidence 
for the underlying mechanism of the arrhythmogenic ffects of 
quinidine. Administration of this compound was associated 
with a significant increase in QT interval dispersion in the 
surface ECG, which is considered to reflect more inhomoge- 
neous ventricular repolarization, thereby facilitating the gene- 
sis of sustained ventricular arrhythmias (23). 
Efficacy of randomized drug therapy. Previous randomized 
trials compared the efficacy of sotalol in preventing recurrent 
atrial fibrillation after successful direct current cardioversion 
with that of quinidine (14) or newer class I antiarrhythmic 
agents uch as propafenone (15). For instance, Juul-MOller et 
al. (14) demonstrated that sotalol and quinidine were equally 
effective over a period of 6 months, but side effects were less 
frequently observed with sotalol. Our present results agree 
with these findings and extend them considerably. During 
short-term therapy with sotalol or quinidine, the class I anti- 
arrhythmic compound proved to be more effective in restoring 
sinus rhythm in our patients. It is conceivable that he response 
rate with sotalol would have been greater with the use of 
higher dosages; nevertheless, our clinical findings are sup- 
ported by recent experimental observations of Wang et al. (24). 
In a dog model of sustained atrial fibrillation they found that 
sotalol's reverse use dependence (i.e., less action potential- 
prolonging efficacy with fast than with slow heart rates [13]) 
limits its ability o terminate very rapid reentrant arrhythmias 
such as atrial fibrillation. In contrast, this phenomenon may 
not limit sotalol's effectiveness in preventing atrial fibrillation 
because this arrhythmia s usually initiated at the slower rates 
of sinus rhythm (24). 
When we included attempted direct current cardioversion 
in our analysis of conversion rates in our study, there were no 
longer significant differences b tween the two groups. Clinical 
characteristics such as the presence of organic heart disease, 
left atrial diameter or left ventricular function were not helpful 
in predicting differences in effectiveness of sotalol or quinidine. 
However, the duration of atrial fibrillation was on average 
significantly shorter in responders to s talol than in patients 
whose sinus rhythm was restored by quinidine. 
After 4 days of continuous drug therapy only -50% of the 
responders had sinus rhythm, whereas the other patients 
required therapy of up to 7 days' duration for conversion of 
atrial fibrillation. Given the safety concerns discussed later, this 
observation implies that patients will need to stay in the 
hospital -> 1 week to assess success or failure of pharmacologic 
conversion therapy. Because sotalol i  as effective as quinidine 
in preventing recurrent episodes of atrial fibrillation (14), an 
alternative therapeutic approach might be the use of primary 
electrical cardioversion with administration f sotalol to main- 
tain sinus rhythm. This procedure may significantly reduce the 
length of the required hospital stay nd its associated costs. 
Safety of randomized therapy. In this and previous con- 
trolled trials in patients with atrial fibrillation (9,14,15), a 
substantial number of patients reported drug-related side 
effects. In our study, the most frequently encountered un- 
wanted reaction due to sotalol was bradycardia, which we had 
prospectively defined as a heart rate <-45 beats/rain. Most of 
the bradycardiac episodes observed wer  not associated with 
symptoms and resolved with dose titration. Only one patient 
had to be withdrawn from sotalol therapy after worsening of 
congestive heart failure. This finding is in accordance with 
other trials in patients with atrial fibrillation (14,25) or vent ic- 
ular arrhythmias (26) treated with sotalol in which this antiar- 
rhythmic compound was surprisingly well to erated even by 
patients with depressed left ventricular function. No patient in 
the present study showed sotalol-induced proarrhythmic 
events. In a retrospective analysis of 1,288 patients with 
ventricular rhythm disorders, the overall incidence of sotalol- 
associated proarrhythmia was 4.3% (27). The most typical 
form of proarrhythmia associated with class IA or class III 
antiarrhythmic drugs is torsade de pointes (28). In the retro- 
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spective analysis just mentioned (27), this tachycardia was 
noted in 24 of the 56 patients with sotalol-induced proarrhyth- 
mia. 
Quinidine was administered in the present study with the 
use of a dosing regimen similar to that previously described 
(4-6,8). The side ffects most frequently encountered with this 
drug were of gastrointestinal origin. However, unwanted reac- 
tions caused withdrawal of the study medication i  10 patients 
in the quinidine group (p = 0.004 vs. the sotalol group). These 
withdrawal rates are comparable to those observed in a 
previous randomized study examining both drugs (14). The 
most worrisome finding of our study was the high incidence of 
quinidine-associated proarrhythmia (29). Three patients had 
ECG-documented torsade de pointes that degenerated into 
ventricular fibrillation in two. In a fourth patient, more mono- 
morphic ventricular tachycardia was observed on telemetry 
after the first dose of quinidine. Whereas it is debatable 
whether this latter event is a relevant proarrhythmic event, the 
three instances of torsade de pointes undoubtedly demonstrate 
the hazards potentially associated with pharmacologic conver- 
sion of atrial fibrillation. Several risk factors for the develop- 
ment of quinidine-associated torsade de pointes have been 
described; hypokalemia andbradycardia re particularly rele- 
vant (28). Thus, it is important to note that in three of our four 
patients with quinidine-related arrhythmia, torsade de pointes 
occurred shortly after restoration of sinus rhythm, when heart 
rate tends to be slow. Similar observations were reported by 
Roden et al. (30), who described eight patients with torsade de 
pointes due to quinidine therapy for atrial fibrillation; in sixof 
the eight, the arrhythmia developed only after conversion of 
atrial fibrillation to sinus rhythm. In our study, quinidine 
plasma concentration was within the normal range in the three 
patients in whom this measurement was available at the time of 
proarrhythmia. Finally, in three of our patients receiving 
quinidine, organization of atrial fibrillation i to atrial flutter in 
association with increases in heart rate preceded the restora- 
tion of sinus rhythm. This pattern is often considered (31) 
another form of drug-induced proarrhythmia. Although the
true incidence of proarrhythmia (particularly in the case of 
sotalol) probably cannot be assessed from our study because of 
its sample size, our findings strikingly support the results 
obtained in retrospective analyses (11,12) of larger patient 
populations with respect to safety of quinidine therapy in atrial 
fibrillation. 
Drug-induced changes in QT dispersion. In an attempt to 
evaluate the electrophysiologic changes induced by the two 
antiarrhythmic drugs that may be responsible for proarrhyth- 
mic reactions, we assessed, in the precordial leads, QT disper- 
sion before and after exposure of patients to quinidine and 
sotalol. This determination, defined as the difference between 
the maximal and the minimal QT interval in any of the ECG 
leads measured, has been shown (17) to indicate nhanced 
inhomogeneity of ventricular repolarization, which is consid- 
ered (23) a prerequisite for the occurrence of polymorphous 
ventricular tachycardia of the torsade de pointes type. In the 
quinidine group, QT dispersion increased significantly over the 
baseline value, whereas only minor changes were observed in 
the sotalol group. In patients with torsade de pointes, QT 
dispersion increased by >50%. The quinidine plasma levels in 
these patients were within normal imits despite this increase in 
QT dispersion. These findings agree with preliminary results 
recently published by Cui et al. (32), who found that QT 
dispersion increased significantly in 60 quinidine-treated pa- 
tients but not in patients receiving amiodarone. Thus, quini- 
dine appears to have the potential of increasing dispersion of 
ventricular ecovery resulting in an electrophysiologic milieu 
favoring the occurrence of sustained ventricular arrhythmias 
(23). As recently pointed out by Statters and co-workers (33), 
determination of QT dispersion--a simple, cheap, noninvasive 
procedure--is important in assessing the therapeutic efficacy 
of antiarrhythmic strategies. These investigators furthermore 
emphasize that nonadjusted, non-rate-corrected QT disper- 
sion measured from simultaneous 6- or 12-lead recordings 
seems likely to provide the most reliable data (33). 
However, the present study comprised a relatively small 
sample size. Thus, our results with respect o QT dispersion 
need to be confirmed in a larger cohort of patients, particularly 
including patients with significant organic heart disease at risk 
for electrolyte disturbances and also ventricular arrhythmias. 
Clinical implications. The results of the present controlled 
trial indicate that sotalol--although not very useful for phar- 
macologic restoration of sinus rhythm--effectively prevents 
recurrent episodes of atrial fibrillation during long-term ther- 
apy. Quinidine, although more effective in restoring sinus 
rhythm, is associated with a significant proarrhythmic risk 
related to its propensity to enhance disparities in ventricular 
repolarization times. Determination of QT dispersion may 
help to predict this arrhythmogenic propensity. The proar- 
rhythmic hazard warrants continuous ECG monitoring (i.e., in 
an observation area providing telemetry monitoring) during 
in-hospital therapy for ~ 1 week, a requirement that has major 
implications in terms of health care resources. Electrical 
cardioversion followed by maintenance of sinus rhythm by 
means of sotalol may thus be a more preferable treatment 
strategy in patients with persistent atrial fibrillation. 
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